 |
|
Recent advances in nonalcoholic fatty liver disease metabolomics
Hwi Young Kim
Clin Mol Hepatol. 2021;27(4):553-559. Published online 2021 Jun 8 DOI: https://doi.org/10.3350/cmh.2021.0127
|
|
Citations to this article as recorded by
Statin use is associated with better
post‐operative
prognosis among patients with hepatitis B
virus‐related
hepatocellular carcinoma
Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin‐Ha Yoon, Beom Kyung Kim
European Journal of Clinical Investigation.2023;[Epub] CrossRef Association of Fatty Liver Index with Incident Diabetes Risk in Patients Initiating Statin–Therapy: A 6-Year Retrospective Study
Georgia Anastasiou, Evangelos Liberopoulos, Ermioni Petkou, Amalia Despoina Koutsogianni, Petros Spyridwnas Adamidis, George Liamis, Evangelia Ntzani, Fotios Barkas
Diagnostics.2023; 13(3): 503. CrossRef Correspondence on Letter regarding “Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF-κB signaling pathways”
Seung Min Lee, Dae Won Jun
Clinical and Molecular Hepatology.2023; 29(1): 171. CrossRef Genetics in non-alcoholic fatty liver disease: The role of risk alleles through the lens of immune response
Silvia Sookoian, Carlos J. Pirola
Clinical and Molecular Hepatology.2023; 29(Suppl): S184. CrossRef Noninvasive imaging biomarkers for liver fibrosis in nonalcoholic fatty liver disease: current and future
Jung Hwan Yu, Han Ah Lee, Seung Up Kim
Clinical and Molecular Hepatology.2023; 29(Suppl): S136. CrossRef Noninvasive serum biomarkers for liver fibrosis in NAFLD: current and future
Tina Reinson, Ryan M. Buchanan, Christopher D. Byrne
Clinical and Molecular Hepatology.2023; 29(Suppl): S157. CrossRef Screening strategy for non-alcoholic fatty liver disease
Saisai Zhang, Lung-Yi Mak, Man-Fung Yuen, Wai-Kay Seto
Clinical and Molecular Hepatology.2023; 29(Suppl): S103. CrossRef Non-invasive biomarkers for liver inflammation in non-alcoholic fatty liver disease: present and
future
Terry Cheuk-Fung Yip, Fei Lyu, Huapeng Lin, Guanlin Li, Pong-Chi Yuen, Vincent Wai-Sun Wong, Grace Lai-Hung Wong
Clinical and Molecular Hepatology.2023; 29(Suppl): S171. CrossRef Baseline Tyrosine Level Is Associated with Dynamic Changes in FAST Score in NAFLD Patients under Lifestyle Modification
Hwi Young Kim, Da Jung Kim, Hye Ah Lee, Joo-Youn Cho, Won Kim
Metabolites.2023; 13(3): 444. CrossRef Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments
Sang Bong Ahn
Clinical and Molecular Hepatology.2023; 29(Suppl): S150. CrossRef The effects of moderate alcohol consumption on non-alcoholic fatty liver disease
Hyunwoo Oh, Won Sohn, Yong Kyun Cho
Clinical and Molecular Hepatology.2023; 29(Suppl): S261. CrossRef Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future
Asako Nogami, Masato Yoneda, Michihiro Iwaki, Takashi Kobayashi, Yasushi Honda, Yuji Ogawa, Kento Imajo, Satoru Saito, Atsushi Nakajima
Clinical and Molecular Hepatology.2023; 29(Suppl): S123. CrossRef Non-alcoholic fatty liver disease: the pathologist’s perspective
Wei-Qiang Leow, Anthony Wing-Hung Chan, Paulo Giovanni L. Mendoza, Regina Lo, Kihan Yap, Haeryoung Kim
Clinical and Molecular Hepatology.2023; 29(Suppl): S302. CrossRef Surveillance of the progression and assessment of treatment endpoints for nonalcoholic steatohepatitis
Yi-wen Shi, Jian-Gao Fan
Clinical and Molecular Hepatology.2023; 29(Suppl): S228. CrossRef Eating, diet, and nutrition for the treatment of non-alcoholic fatty liver disease
Georg Semmler, Christian Datz, Michael Trauner
Clinical and Molecular Hepatology.2023; 29(Suppl): S244. CrossRef MAFLD enhances clinical practice for liver disease in the Asia-Pacific region
Takumi Kawaguchi, Tsubasa Tsutsumi, Dan Nakano, Mohammed Eslam, Jacob George, Takuji Torimura
Clinical and Molecular Hepatology.2022; 28(2): 150. CrossRef Characteristics of Urine Organic Acid Metabolites in Nonalcoholic Fatty Liver Disease Assessed Using Magnetic Resonance Imaging with Elastography in Korean Adults
Ji-Hee Haam, Yun Kyong Lee, Eunkyung Suh, Young-Sang Kim
Diagnostics.2022; 12(5): 1199. CrossRef Advances in pediatric non-alcoholic fatty liver disease: From genetics to lipidomics
Simona Riccio, Rosa Melone, Caterina Vitulano, Pierfrancesco Guida, Ivan Maddaluno, Stefano Guarino, Pierluigi Marzuillo, Emanuele Miraglia del Giudice, Anna Di Sessa
World Journal of Clinical Pediatrics.2022; 11(3): 221. CrossRef Effect of metabolic dysfunction‐associated fatty liver disease on liver cancer risk in a population with chronic hepatitis B virus infection: A nationwide study
Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin‐Ha Yoon, Beom Kyung Kim
Hepatology Research.2022; 52(12): 975. CrossRef The emerging roles of extracellular vesicles as intercellular messengers in liver physiology and pathology
Youngseok Lee, Jong-Hoon Kim
Clinical and Molecular Hepatology.2022; 28(4): 706. CrossRef Comparable Mortality Between Asian Patients with Chronic Hepatitis B Under Long-Term Antiviral Therapy vs Matched Control: A Population-Based Study
Byungyoon Yun, Juyeon Oh, Sang Hoon Ahn, Jin-Ha Yoon, Beom Kyung Kim
American Journal of Gastroenterology.2022;[Epub] CrossRef Rhamnetin ameliorates non-alcoholic steatosis and hepatocellular carcinoma in vitro
Mahmoud A. Shatta, Marwa O. El-Derany, Abdullah A. Gibriel, Hala O. El-Mesallamy
Molecular and Cellular Biochemistry.2022;[Epub] CrossRef The Evidence Surrounding Non-Alcoholic Fatty Liver Disease in Individuals with Cancer: A Systematic Literature Review
Elena S. George, Surbhi Sood, Nicole Kiss, Robin M. Daly, Amanda J. Nicoll, Stuart K. Roberts, Brenton J. Baguley
Current Oncology.2022; 30(1): 48. CrossRef Study on the Hepatoprotection of Schisandra chinensis Caulis Polysaccharides in Nonalcoholic Fatty Liver Disease in Rats Based on Metabolomics
Yanbo Feng, Han Li, Cong Chen, Hao Lin, Guangyu Xu, He Li, Chunmei Wang, Jianguang Chen, Jinghui Sun
Frontiers in Pharmacology.2021;[Epub] CrossRef
|